Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly—Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying

Henry P. Parkman; Daniel S. Rim; Jonathan R. Anolik; Simin Dadparvar; Alan H. Maurer

doi:10.2967/jnmt.123.266800

Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly—Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying

Henry P. Parkman
, Daniel S. Rim
, Jonathan R. Anolik
, Simin Dadparvar
, Alan H. Maurer

Department of Radiology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Glucagonlike peptide-1 (GLP-1) receptor agonists (RAs) are being increasingly used for glycemic control in patients with diabetes and for weight loss and weight management in obese subjects. There has been recent public awareness of the potential of GLP-1 RAs to delay gastric emptying and cause gastroparesis. By delaying gastric emptying, these agents can complicate the clinical evaluation of patients on these drugs by affecting diagnostic testing for gastroparesis. This article discusses GLP-1 RAs and their effects on gastric emptying, gastric food retention, and gastroparesis. This article highlights how physicians should be attuned to the gastric side effects of these popular therapeutic agents for blood glucose control in people with diabetes and for weight loss and weight management in obese patients.

Original language	English (US)
Pages (from-to)	3-7
Number of pages	5
Journal	Journal of Nuclear Medicine Technology
Volume	52
Issue number	1
DOIs	https://doi.org/10.2967/jnmt.123.266800
State	Published - Mar 1 2024

All Science Journal Classification (ASJC) codes

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2967/jnmt.123.266800

Cite this

@article{7ce7f4b9aafd4d4784583ce557191cd0,

title = "Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly—Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying",

abstract = "Glucagonlike peptide-1 (GLP-1) receptor agonists (RAs) are being increasingly used for glycemic control in patients with diabetes and for weight loss and weight management in obese subjects. There has been recent public awareness of the potential of GLP-1 RAs to delay gastric emptying and cause gastroparesis. By delaying gastric emptying, these agents can complicate the clinical evaluation of patients on these drugs by affecting diagnostic testing for gastroparesis. This article discusses GLP-1 RAs and their effects on gastric emptying, gastric food retention, and gastroparesis. This article highlights how physicians should be attuned to the gastric side effects of these popular therapeutic agents for blood glucose control in people with diabetes and for weight loss and weight management in obese patients.",

author = "Parkman, \{Henry P.\} and Rim, \{Daniel S.\} and Anolik, \{Jonathan R.\} and Simin Dadparvar and Maurer, \{Alan H.\}",

year = "2024",

month = mar,

day = "1",

doi = "10.2967/jnmt.123.266800",

language = "English (US)",

volume = "52",

pages = "3--7",

journal = "Journal of Nuclear Medicine Technology",

issn = "0091-4916",

publisher = "Society of Nuclear Medicine Inc.",

number = "1",

}

Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly—Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying. / Parkman, Henry P.; Rim, Daniel S.; Anolik, Jonathan R. et al.
In: Journal of Nuclear Medicine Technology, Vol. 52, No. 1, 01.03.2024, p. 3-7.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Glucagonlike Peptide-1 Receptor Agonists

T2 - The Good, the Bad, and the Ugly—Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying

AU - Parkman, Henry P.

AU - Rim, Daniel S.

AU - Anolik, Jonathan R.

AU - Dadparvar, Simin

AU - Maurer, Alan H.

PY - 2024/3/1

Y1 - 2024/3/1

N2 - Glucagonlike peptide-1 (GLP-1) receptor agonists (RAs) are being increasingly used for glycemic control in patients with diabetes and for weight loss and weight management in obese subjects. There has been recent public awareness of the potential of GLP-1 RAs to delay gastric emptying and cause gastroparesis. By delaying gastric emptying, these agents can complicate the clinical evaluation of patients on these drugs by affecting diagnostic testing for gastroparesis. This article discusses GLP-1 RAs and their effects on gastric emptying, gastric food retention, and gastroparesis. This article highlights how physicians should be attuned to the gastric side effects of these popular therapeutic agents for blood glucose control in people with diabetes and for weight loss and weight management in obese patients.

AB - Glucagonlike peptide-1 (GLP-1) receptor agonists (RAs) are being increasingly used for glycemic control in patients with diabetes and for weight loss and weight management in obese subjects. There has been recent public awareness of the potential of GLP-1 RAs to delay gastric emptying and cause gastroparesis. By delaying gastric emptying, these agents can complicate the clinical evaluation of patients on these drugs by affecting diagnostic testing for gastroparesis. This article discusses GLP-1 RAs and their effects on gastric emptying, gastric food retention, and gastroparesis. This article highlights how physicians should be attuned to the gastric side effects of these popular therapeutic agents for blood glucose control in people with diabetes and for weight loss and weight management in obese patients.

UR - https://www.scopus.com/pages/publications/85187203813

UR - https://www.scopus.com/pages/publications/85187203813#tab=citedBy

U2 - 10.2967/jnmt.123.266800

DO - 10.2967/jnmt.123.266800

M3 - Article

C2 - 38443105

AN - SCOPUS:85187203813

SN - 0091-4916

VL - 52

SP - 3

EP - 7

JO - Journal of Nuclear Medicine Technology

JF - Journal of Nuclear Medicine Technology

IS - 1

ER -

Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly—Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this